行情

RETA

RETA

Reata制药
NASDAQ

实时行情|Nasdaq Last Sale

92.78
+0.96
+1.05%
交易中 10:45 09/20 EDT
开盘
92.06
昨收
91.82
最高
93.89
最低
92.00
成交量
10.41万
成交额
--
52周最高
104.53
52周最低
47.50
市值
27.93亿
市盈率(TTM)
-22.8798
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RETA 新闻

  • 加拿大FirstQuantum正吸引全球矿业企业初步收购兴趣
  • 新浪美股.25分钟前
  • 戴姆勒停止内燃机研发闹乌龙?网上现两个版本说法
  • 新京报.30分钟前
  • iPhone 11线下开售:普通配色现场可买 暗夜绿断货
  • 澎湃新闻.1小时前
  • 瑞信:美国股票面临170亿美元的退休基金卖盘
  • 新浪财经综合.1小时前

更多

所属板块

生物技术和医学研究
+0.82%
制药与医学研究
+1.17%

热门股票

名称
价格
涨跌幅

RETA 简况

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
展开

Webull提供Reata Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。